Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction

Exclusion Criteria

• •Patient with clinically significant illnesses or recent hospitalization (within 60 days) which could compromise participation in the study in the judgment of the investigator, including: uncontrolled diabetes; active or uncontrolled infection; Confirmed diagnosis of HIV infection; uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled cardiac arrhythmia.
• •Patient with any other auto immune disease, major chronic inflammatory disease or syndrome requiring significant treatment within the past year.
• •Patients who are pregnant or breast feeding
• •Patient receiving or has received any investigational drug within 30 days prior (or is currently using an investigational device)
• •Patients with prior (within 4 weeks) or concurrent treatment with oral steroids, or protein-based therapy (i.e. TNFa)
• •Patients with positive urine screen for drugs of abuse except when receiving a prescribed medication for a known indication
• •Patients with Grade 2 or above hepatic encephalopathy.
• •Patients who donated blood or experienced a significant blood loss (\>450 mL) within 8 weeks of screening
• •Patients with a history of bleeding varices within 12 weeks of screening.
• •Patients with psychiatric illness or other condition that would limit compliance with study requirements.